Physician profile
Anna B Nemeth
NPI 1821442120
$4,316.30
in general payments reported to CMS, 2019-2025
17 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $450 · 2021: $480 · 2022: $811 · 2023: $528 · 2024: $845 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,943.50 | 2020-2025 | Hoffmann, Prostep Mica, Augment Injectable |
| Integra Lifesciences Corporation | $1,313.70 | 2019-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kci USA, INC. | $198.95 | 2020-2023 | Activ.A.C., V.A.C. Dermatac, V.A.C. Veraflo |
| Bioventus LLC | $166.00 | 2025 | Exogen Ultrasound Bone Healing System |
| Derma Sciences, INC. | $145.22 | 2019 | |
| Allergan, INC. | $91.56 | 2019-2020 | |
| Abbvie INC. | $86.18 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $85.44 | 2023-2025 | Nuzyra |
| Crossroads Extremity Systems, LLC | $68.43 | 2019 | |
| Convatec INC. | $56.54 | 2022-2023 | |
| Suvon Surgical LLC | $38.46 | 2024 | |
| Solventum Corporation | $33.07 | 2024 | V.A.C. Veraflo Cleanse Choice, V.A.C. Veraflo, V.A.C.Ulta |
| Smith+Nephew, INC. | $22.94 | 2020 | |
| Hydrofera LLC | $21.64 | 2025 | Hydrofera Blue |
| Melinta Therapeutics, LLC | $17.68 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Oxygen Therapy INC. | $14.80 | 2020 | |
| Kerecis Limited | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Nemeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.